Clinical TrialAug 7, 2026, 04:48 PM
AbCellera to Announce Phase 2 ABCL635 Trial Data on Aug 10
AI Summary
AbCellera Biologics Inc. announced it will release top-line data from its Phase 2 trial evaluating ABCL635 for the treatment of moderate-to-severe vasomotor symptoms (VMS) due to menopause. The data will be released before market open on Monday, August 10, 2026. The company will also host an investor conference call and live webcast at 4:30 a.m. PT / 7:30 a.m. ET on the same day to discuss the results.
Key Highlights
- AbCellera to release top-line data from Phase 2 trial of ABCL635.
- Data release scheduled for Monday, August 10, 2026, before market open.
- Investor conference call and live webcast at 4:30 a.m. PT / 7:30 a.m. ET.
- ABCL635 is for moderate-to-severe vasomotor symptoms (VMS) due to menopause.
- ABCL635 is a potential first-in-class antibody drug targeting NK3R.
- Phase 2 trial (NCT07118891) involved approximately 80 postmenopausal women.
Price Impact
More from ABCL